Department of Medicine
Faculty Profiles by Division

Department of Medicine

Faculty Profiles

[Return To Index page]
photo Robbie B. Mailliard, PhD

Infectious Diseases

Associate Professor of Medicine

Associate Director of The Pitt Systems Biology & Biostatistics Core of the CWRU/Pitt Center for AIDS Research (Rustbelt CFAR)

Email: rbm19@pitt.edu

Phone: 412-624-3848

Contact
Office: Scaife Hall, 8th Floor S857
3550 Terrace Street
Pittsburgh, PA 15261
 
Phone: 412-624-3848
Fax:
E-mail: rbm19@pitt.edu
Administrative Assistant:
Holly A. Bilben
Address: Scaife Hall, 8th Floor
3550 Terrace Street
Pittsburgh, PA 15261
Email: hob1@pitt.edu
Phone: 412-648-4227
Administrative Assistant:
Rhonda Cunningham-Wicks
Address: Scaife Hall Ste 817
3550 Terrace Street
Pittsburgh, PA 15261
Email: rhondacw@pitt.edu
Education and Training
Education
PhD (Immunology), University of Amsterdam, 2006
BS (Microbiology), University of Pittsburgh, 1990
Post-Doc (Tumor Immunology), University of Pittsburgh Cancer Institute, Division of Surgical Oncology, 2007
Research Interest
Dr. Mailliard’s research focuses on the central role played by dendritic cells (DCs) in the induction and regulation of the immune response. He is also interested in the non-classical “helper” functions of NK cells and CD8+ cytotoxic T cells and their influence on DC function during infection and vaccination. His goal is to have a better understanding of basic immunity for the purpose of developing more effective cellular based immunotherapy strategies to treat chronic diseases including HIV and cancer. His work has led to the development of the first clinically applicable type-1 polarized dendritic cell-based vaccine platform (alpha-DC1), which is currently being explored in clinical trials for the treatment of different cancers and HIV. His lab is currently exploring the use of DCs as an HIV immunotherapeutic “kick and kill” tool to both drive HIV latency reversal and to prime cytotoxic T cell responses against the infected CD4+ T cell reservoir as a functional cure strategy. He is a co-investigator of the Mulitcenter AIDS Cohort Study/ Women’s Interagency HIV Study (MACS/WIHS Combined Cohort Study) and the the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) network, and he serves as the Associate Director of The Systems Biology & Biostatistics Core of the CWRU/Pitt Center for AIDS Research (Rustbelt CFAR).
Clinical Interest
HIV Immunotherapy
Cancer Immunotherapy
Publications
For my complete bibliography, Click Here.
Selected Publications:
Mailliard, RB., Wankowicz-Kalinska, A., Cai, Q., Wesa, A., Hilkens, CM., Kapsenberg, ML., Kirkwood, JM., Storkus, WJ., Kalinski, P. Alpha-Type-1 Polarized Dendritic Cells: a Novel Immunization Tool with Optimized CTL-Inducing Activity. Cancer Research. 2004; 64 (17).: 5934-7.
Mailliard, RB., Alber, SM., Shen, H., Watkins, SC., Kirkwood, JM., Herberman, RB., Kalinski, P. IL-18-Induced CD83+CCR7+ NK Helper Cells. The Journal of Experimental Medicine. 2005; 202 (7).: 941-53.
Mailliard, RB., Smith, KN., Fecek, RJ., Rappocciolo, G., Nascimento, EJ., Marques, ET., Watkins, SC., Mullins, JI., Rinaldo, CR. Selective Induction of CTL Helper Rather Than Killer Activity by Natural Epitope Variants Promotes Dendritic Cell-Mediated HIV-1 Dissemination. Journal of Immunology. 2013; 191 (5).: 2570-80.
Zaccard, CR., Watkins, SC., Kalinski, P., Fecek, RJ., Yates, AL., Salter, RD., Ayyavoo, V., Rinaldo, CR., Mailliard, RB. CD40L Induces Functional Tunneling Nanotube Networks Exclusively in Dendritic Cells Programmed by Mediators of Type 1 Immunity. Journal of Immunology. 2015; 194 (3).: 1047-56.
Garcia-Bates, TM, Palma, ML., Gambotto, A., Macatangay, BJC., Ferris, RL., Rinaldo, CR ., Mailliard, RB. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell Mediated Induction and Regulation of HIV-1 Specific Cytotoxic T Cell Responses. Journal of Virology. 2019; 93(5).: e02035-18.
Kristoff, J., Palma, ML., Garcia-Bates, TM., Shen, C., Sluis-Cremer, N., Gupta, P., Rinaldo, CR., Mailliard, RB. Type 1-Programmed Dendritic Cells Drive Antigen-Specific Latency Reversal and Immune Elimination of Persistent HIV-1. eBioMedicine. 2019; 43: 295-306.
Anderko, RR., Rinaldo, CR., Mailliard, RB. IL-18 Responsiveness Defines Limitations in Immune ‘Help’ for Specialized FcR?– NK Cells. Journal of Immunology. 2020; 205(12).: 3429-3442.
Biradar, S., Agarwal, Y., Lotze, MT., Bility, MT., Mailliard, RB. The BLT Humanized Mouse Model as a Tool for Studying Human Gamma Delta T Cell-HIV Interactions in Vivo. Frontiers in Immunology. 2022; 13: 18:881607.
Anderko, RR., Mailliard, RB. Mapping the Interplay Between NK Cells and HIV: Therapeutic Implications. Journal of Leukocyte Biology. 2023; 113(2).: 109–138.
Garcia-Bates, TM., Palma, ML., Anderko, RR., Hsu, DC., Ananworanich, J., Kober, BT., Gaiha, GD., Phanuphak, N., Thomas, R., Tovanabutra, S., Walker, BD., Mellors, JW., Piazza, PA., Kroon, E., Riddler, SA., Michael, NL., Rinaldo, CR., Mailliard RB, on behalf of the I4C and RV254 Study Groups. Dendritic Cells Focus CTL Responses Toward Highly Conserved HIV Epitopes. EBioMedicine. 2021; 64: 103217.
Notable Achievements
Member, The Society for Leukocyte Biology, 2012-Present
Member, American Association of Immunologists (AAI), 2013-Present
Member, International Aids Society (IAS), 2015-Present
Frontiers in Immunology - Editorial Board Member (Section: Antigen Presenting Cell Biology), 2020-Present
Pathogens - Editorial Board Member (Section: Immunological Responses and Immune Defense Mechanisms), 2021-Present
Frontiers in Virology - Associate Editor (Section: Modeling of Viral Replication and Pathogenesis), 2021-Present
amfAR, Foundation for AIDS Research, HIV Cure Target Grants Review Panel, 2022
NIH/NAID, R21-AI-041 Special Emphasis Review Panel: Innate Immune Memory Impacting HIV Acquisition and/or Control, 2022
NIH/NAID, HIV Immunopathogenesis and Vaccine Development (HIVD) Study Section, 2022-2023
Patent: U.S. Provisional 62/867.501 International # PCT/USA2020/03984 (Pitt Reference 04973) Compositions and Methods for Detecting HIV Latency, Treating HIV Infection, and Reversing HIV Latency, 2020